Last updated on November 2018

A Phase 2 Study of Cabozantinib in Japanese Patients With Advanced Hepatocellular Carcinoma


Brief description of study

The purpose of this study is to evaluate the efficacy and safety of Cabozantinib in Japanese patients with advanced hepatocellular carcinoma (HCC) who have received prior systemic anticancer therapy.

Detailed Study Description

The drug being tested in this study is called Cabozantinib. Cabozantinib is being tested to treat advanced hepatocellular carcinoma in Japanese patients. This study will look at the efficacy and safety of Cabozantinib.

The study will enroll approximately 32 patients. Participants will be assigned to Cohort A (at least 17 participants) or Cohort B (approximately 15 participants) and will receive the following treatment. Participants who have received prior sorafenib will enroll to Cohort A and participants who have not received prior sorafenib will enroll to Cohort B.

  • Cabozantinib 60 mg

All participants will be asked to take one tablet of cabozantinib once daily in the fasted state (dose at least 2 hours after meal and no more food intake for 1 hour postdose) throughout the study.

This multi-center trial will be conducted in Japan. The overall time to participate in this study is approximately at most 3 years. Participants will make multiple visits to the clinic during the treatment and posttreatment period, including a follow-up assessment after last dose of study drug.

Clinical Study Identifier: NCT03586973

Contact Investigators or Research Sites near you

Start Over

Takeda Study Registration Call Center

National Cancer Center Hospital East
Kashiwa, Japan
5.16miles
  Connect »